Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis

Psoriasis Area Severity Index Score,Adverse Events

Psoriasis is a persistent condition which demands prolonged management, so it puts heavy
 financial as well as psychological burden on patients. Severe psoriasis makes work impossible
 for patients. If it affects exposed parts of the body, it may lead to decrease in
 self-esteem, social avoidance, and shame. Patients with even mild form of psoriasis have high
 stigma as compared to other cutaneous diseases. As a result, psoriasis affected individuals
 experience greater difficulty in social interactions and employment. Patients experience
 symptoms in psoriasis includes bleeding, itching and inflamed joints. Psoriatic patients
 develop psoriatic arthritis approximately at 40 years of age which contributes to fatigue in
 these individuals. Moreover, early age onset of psoriasis leads to more physical impairment.
 Hence, patients get trapped in a vicious cycle as stress leads to further aggravation of
 disease. The European Medicine Agency has given its approval regarding the usage of
 INFLIXIMAB bio similar REMSIMA for psoriasis after taking in consideration its effectiveness
 from other studies conducted on ankylosing spondylitis and rheumatoid arthritis. This study
 is being conducted as no data is present on REMSIMA SC in psoriasis patient in Pakistan.